Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statement
KLRS•Initial beneficial ownership filing
Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, filed an initial beneficial ownership statement.
- Kalaris Therapeutics officer Amy O’Leary Vandekop reported 948 common shares, plus stock options for 47,415 shares at USD 6.81-7.31.
